Organon & Co. Shareholders Approve Sun Pharma Merger Deal
Shareholders of Organon & Co. (NYSE:OGN) voted to approve the company's proposed merger with Sun Pharmaceutical Holdings USA, Inc. during a virtual special meeting on July 23, 2026. The merger agreement, dated April 26, 2026, involves Sun Pharma's merger subsidiary combining with Organon, which will survive as a wholly owned subsidiary of Sun Pharma USA. Preliminary voting results showed the requisite votes were cast in favor of adopting the merger agreement. Shareholders also gave non-binding advisory approval to potential merger-related compensation for Organon's named executive officers. The meeting established a quorum with 74.5% of outstanding shares represented. Final certified voting results will be filed with the SEC in a Form 8-K. The deal marks a major step in the acquisition of Organon by Sun Pharma.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection